BPH Surgical Treatment Market by Type (TURP, Laser, Rezum, Urolift, Ablation, PAE), Drug Type (Alpha Blocker (Alfuzosin), Alpha Reductase Inhibitor (Dutastride), Therapy (Mono, Combination), End Users (Hospitals) - Global Forecast to 2030

1 INTRODUCTION 29 1.1 STUDY OBJECTIVES 29 1.2 MARKET DEFINITION 29 1.3 STUDY SCOPE 30 1.3.1 MARKET SCOPE 30 1.3.2 INCLUSIONS & EXCLUSIONS 31 1.3.3 YEARS CONSIDERED 31 1.3.4 CURRENCY CONSIDERED 32 1.4 STAKEHOLDERS 32 1.5 LIMITATIONS 32 1.6 SUMMARY OF CHANGES 32 2 RESEARCH METHODOLOGY 34 2.1 RESEARCH DATA 34 2.1.1 SECONDARY DATA 34 2.1.1.1 Key data from secondary sources 35 2.1.2 PRIMARY DATA 36 2.1.2.1 Primary sources 36 2.1.2.2 Key data from primary sources 37 2.1.2.3 Key industry insights 38 2.1.2.4 Breakdown of primary interviews 38 2.2 MARKET SIZE ESTIMATION 39 2.2.1 BOTTOM-UP APPROACH 39 2.2.1.1 Approach 1: Company revenue estimation approach, by type 40 2.2.1.2 Approach 1: Company revenue estimation approach, by drug type 41 2.2.2 TOP-DOWN APPROACH 44 2.3 MARKET BREAKDOWN & DATA TRIANGULATION 45 2.4 MARKET SHARE ANALYSIS 46 2.4.1 STUDY ASSUMPTIONS 46 2.4.2 GROWTH RATE ASSUMPTIONS 46 2.5 RESEARCH LIMITATIONS 47 2.5.1 METHODOLOGY-RELATED LIMITATIONS 47 2.5.2 SCOPE-RELATED LIMITATIONS 47 2.6 RISK ASSESSMENT 47 3 EXECUTIVE SUMMARY 48   4 PREMIUM INSIGHTS 53 4.1 BPH SURGICAL TREATMENT MARKET OVERVIEW 53 4.2 NORTH AMERICA: BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE AND COUNTRY (2024) 54 4.3 BPH SURGICAL TREATMENT MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 55 4.4 BPH SURGICAL TREATMENT MARKET: REGIONAL MIX (2024–2030) 56 5 MARKET OVERVIEW 57 5.1 INTRODUCTION 57 5.2 MARKET DYNAMICS 57 5.2.1 DRIVERS 58 5.2.1.1 Expanding aging population and increasing prevalence of benign prostatic hyperplasia 58 5.2.1.2 Rising cases of obesity in males 58 5.2.1.3 Growing preference for minimally invasive surgeries 59 5.2.2 RESTRAINTS 60 5.2.2.1 Side effects associated with BPH medications 60 5.2.2.2 High cost of BPH surgical treatment 61 5.2.3 OPPORTUNITIES 61 5.2.3.1 High growth potential of emerging economies 61 5.2.3.2 Favorable funding investments for BHP drug development 62 5.2.4 CHALLENGES 63 5.2.4.1 Shortage of skilled professionals 63 5.2.4.2 Low awareness regarding prostate health 63 5.2.4.3 Product recalls 64 5.3 VALUE CHAIN ANALYSIS 64 5.4 SUPPLY CHAIN ANALYSIS 66 5.5 ECOSYSTEM ANALYSIS 67 5.6 PORTER’S FIVE FORCES ANALYSIS 69 5.6.1 THREAT OF NEW ENTRANTS 70 5.6.2 THREAT OF SUBSTITUTES 70 5.6.3 BARGAINING POWER OF BUYERS 70 5.6.4 BARGAINING POWER OF SUPPLIERS 70 5.6.5 INTENSITY OF COMPETITIVE RIVALRY 70 5.7 KEY STAKEHOLDERS & BUYING CRITERIA 71 5.7.1 KEY STAKEHOLDERS IN BUYING PROCESS 71 5.7.2 BUYING CRITERIA 71 5.8 REGULATORY SCENARIO 72 5.8.1 PHARMACEUTICAL INDUSTRY 72 5.8.1.1 Regulatory requirements 73 5.8.1.1.1 EU regulations 73 5.8.1.1.2 US regulations 73 5.8.2 MEDICAL DEVICES INDUSTRY 73 5.8.2.1 US 73 5.8.2.2 Canada 74 5.8.2.3 Europe 75 5.8.2.4 Asia Pacific 76 5.8.2.4.1 Japan 76 5.8.2.4.2 China 77 5.8.2.4.3 India 78 5.8.2.5 Latin America 79 5.8.2.5.1 Brazil 79 5.8.2.5.2 Mexico 79 5.8.2.6 Middle East 79 5.8.2.7 Africa 80 5.8.3 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 80 5.9 PRICING ANALYSIS 82 5.9.1 AVERAGE SELLING PRICE TREND FOR UROLIFT, BY REGION, 2021−2023 82 5.9.2 AVERAGE SELLING PRICING TREND FOR AVODART, BY REGION, 2021−2023 82 5.9.3 AVERAGE SELLING PRICING TREND FOR BPH SURGICAL TREATMENT PROCEDURES, 2021−2023 83 5.10 TECHNOLOGY ANALYSIS 83 5.10.1 KEY TECHNOLOGIES 83 5.10.1.1 Minimally invasive surgical techniques 83 5.10.2 COMPLEMENTARY TECHNOLOGIES 84 5.10.2.1 Robotic & AI-assisted surgical systems 84 5.10.3 ADJACENT TECHNOLOGIES 84 5.10.3.1 MRI-ultrasound imaging 84 5.11 PESTLE ANALYSIS 85 5.12 PATENT ANALYSIS 86 5.13 TRADE ANALYSIS 90 5.13.1 TRADE ANALYSIS FOR ENDOSCOPES 90 5.13.2 TRADE ANALYSIS FOR TADALAFIL 91 5.14 KEY CONFERENCES & EVENTS, 2025−2026 92 5.15 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 93 5.16 IMPACT OF GENERATIVE AI/AI ON BPH SURGICAL TREATMENT MARKET 94 5.17 INVESTMENT & FUNDING SCENARIO 94 6 BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE 95 6.1 INTRODUCTION 96 6.1.1 ALPHA-BLOCKERS 98 6.1.1.1 Tamsulosin 100 6.1.1.1.1 Oldest prescribed drug with minimal effects on blood pressure to fuel uptake 100 6.1.1.2 Silodosin 103 6.1.1.2.1 Launch of generics to boost demand 103 6.1.1.3 Alfuzosin 105 6.1.1.3.1 Associated side effects to restrain market adoption 105 6.1.1.4 Doxazosin 108 6.1.1.4.1 Ability to provide long-term results to fuel uptake 108 6.1.1.5 Other alpha-blockers 111 6.1.2 5-ALPHA REDUCTASE INHIBITORS 113 6.1.2.1 Dutasteride 116 6.1.2.1.1 Slow but gradual reduction in symptoms to boost demand 116 6.1.2.2 Finasteride 118 6.1.2.2.1 Ability to decrease PSA levels to support market growth 118 6.1.3 OTHER DRUG TYPES 121 7 BPH SURGICAL TREATMENT MARKET, BY TYPE 124 7.1 INTRODUCTION 125 7.1.1 TRANSURETHRAL RESECTION OF THE PROSTATE (TURP) 128 7.1.1.1 Gold standard for BPH treatment to boost demand 128 7.1.2 LASER SURGERIES 131 7.1.2.1 Evolution in lasers and high efficacy to boost demand 131 7.1.3 UROLIFT PROCEDURES 133 7.1.3.1 High safety and convenience to boost demand 133 7.1.4 REZŪM PROCEDURES 136 7.1.4.1 Convenience of being conducted in outpatient settings to support market growth 136 7.1.5 ROBOT-ASSISTED WATERJET ABLATION 138 7.1.5.1 Advanced real-time capabilities with image-guided features to propel market 138 7.1.6 PROSTATIC STENTS 141 7.1.6.1 Temporarily designed for short-term use to support market growth 141 7.1.7 TRANSURETHRAL MICROWAVE THERMOTHERAPY (TUMT) 144 7.1.7.1 Lower risk of bleeding without hospitalization to fuel market 144 7.1.8 TRANSURETHRAL NEEDLE ABLATION OF THE PROSTATE (TUNA) 146 7.1.8.1 Favorable reimbursement policies to boost demand 146 7.1.9 PROSTATIC ARTERIAL EMBOLIZATION (PAE) 149 7.1.9.1 Minimally invasive technique to fuel uptake 149 7.1.10 OTHER PROCEDURES 152 8 BPH SURGICAL TREATMENT MARKET, BY THERAPY 155 8.1 INTRODUCTION 156 8.2 MONOTHERAPY 158 8.2.1 UTILIZATION OF SINGLE MEDICATION TO PROPEL MARKET 158   8.3 COMBINATION DRUG THERAPY 160 8.3.1 HIGH UTILIZATION FOR PATIENTS WITH RAPID PROGRESSION RATES TO DRIVE MARKET 160 9 BPH SURGICAL TREATMENT MARKET, BY END USER 164 9.1 INTRODUCTION 165 9.2 HOSPITALS 165 9.2.1 HIGH PURCHASING POWER FOR ADVANCED BPH SURGICAL EQUIPMENT TO DRIVE MARKET 165 9.3 AMBULATORY SURGERY CENTERS & CLINICS 168 9.3.1 LOWER COST AND SHORTER PATIENT STAYS TO PROPEL MARKET 168 9.4 HOME CARE SETTINGS 171 9.4.1 CONVENIENCE AND COST-EFFICIENT BENEFITS TO FUEL MARKET 171 10 BPH SURGICAL TREATMENT MARKET, BY REGION 175 10.1 INTRODUCTION 176 10.2 NORTH AMERICA 177 10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 177 10.2.2 US 181 10.2.2.1 Presence of key medical device manufacturers to boost demand 181 10.2.3 CANADA 184 10.2.3.1 Favorable federal funding for advanced BPH products to fuel market 184 10.3 EUROPE 187 10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 188 10.3.2 GERMANY 191 10.3.2.1 Increasing healthcare expenditure to drive market 191 10.3.3 UK 194 10.3.3.1 Availability of innovative treatment options for UTIs to drive market 194 10.3.4 FRANCE 197 10.3.4.1 Favorable private & public healthcare investments to fuel market 197 10.3.5 ITALY 200 10.3.5.1 Rising geriatric population and subsequent rise in obesity to propel market 200 10.3.6 SPAIN 203 10.3.6.1 Increasing uptake of UroLift procedures to drive market 203 10.3.7 REST OF EUROPE 206 10.4 ASIA PACIFIC 209 10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 209 10.4.2 JAPAN 214 10.4.2.1 Mandatory health insurance programs to fuel uptake 214 10.4.3 CHINA 217 10.4.3.1 Rising demand for diagnostic procedures to drive market 217 10.4.4 INDIA 220 10.4.4.1 Expanding target patient population to drive market 220 10.4.5 AUSTRALIA 223 10.4.5.1 High prevalence of obesity to support market growth 223 10.4.6 REST OF ASIA PACIFIC 226 10.5 LATIN AMERICA 229 10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 229 10.5.2 BRAZIL 232 10.5.2.1 Rising incidence of cancer to support market growth 232 10.5.3 MEXICO 235 10.5.3.1 Popularity in medical tourism to drive market 235 10.5.4 REST OF LATIN AMERICA 238 10.6 MIDDLE EAST & AFRICA 241 10.6.1 DEMAND FOR ADVANCED HEALTHCARE DIAGNOSTICS TO FUEL UPTAKE 241 10.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 242 10.7 GCC COUNTRIES 245 10.7.1 RISING HEALTHCARE BUDGETS AND GROWING AWARENESS OF BPH TO SUPPORT MARKET GROWTH 245 10.7.2 MACROECONOMIC OUTLOOK FOR GCC COUNTRIES 246 11 COMPETITIVE LANDSCAPE 250 11.1 OVERVIEW 250 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 250 11.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN BPH SURGICAL TREATMENT MARKET 250 11.3 REVENUE ANALYSIS, 2021−2023 252 11.4 MARKET SHARE ANALYSIS, 2023 253 11.5 COMPANY EVALUATION MATRIX, BY DRUG TYPE: KEY PLAYERS, 2023 256 11.5.1 STARS 256 11.5.2 EMERGING LEADERS 256 11.5.3 PERVASIVE PLAYERS 256 11.5.4 PARTICIPANTS 256 11.6 COMPANY EVALUATION MATRIX, BY TYPE: KEY PLAYERS, 2023 258 11.6.1 STARS 258 11.6.2 EMERGING LEADERS 258 11.6.3 PERVASIVE PLAYERS 258 11.6.4 PARTICIPANTS 258 11.6.5 COMPANY FOOTPRINT: KEY PLAYERS (DRUG TYPE AND TYPE), 2023 260 11.6.5.1 Company footprint 260 11.6.5.2 Region footprint 261 11.6.5.3 Drug type footprint 261 11.6.5.4 Type footprint 262 11.6.5.5 End-user footprint 262   11.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 263 11.7.1 PROGRESSIVE COMPANIES 263 11.7.2 RESPONSIVE COMPANIES 263 11.7.3 DYNAMIC COMPANIES 263 11.7.4 STARTING BLOCKS 263 11.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 265 11.7.5.1 Detailed list of key startups/SMEs 265 11.7.5.2 Competitive benchmarking of key startups 265 11.8 COMPANY VALUATION & FINANCIAL METRICS 266 11.9 BRAND/PRODUCT COMPARISON 267 11.10 COMPETITIVE SCENARIO 267 11.10.1 PRODUCT LAUNCHES & APPROVALS 267 11.10.2 DEALS 268 11.10.3 EXPANSIONS 269 12 COMPANY PROFILES 270 12.1 KEY PLAYERS 270 12.1.1 GLAXOSMITHKLINE PLC 270 12.1.1.1 Business overview 270 12.1.1.2 Products offered 272 12.1.1.3 Recent developments 272 12.1.1.3.1 Deals 272 12.1.1.4 MnM view 273 12.1.1.4.1 Key strengths 273 12.1.1.4.2 Strategic choices 273 12.1.1.4.3 Weaknesses & competitive threats 273 12.1.2 ELI LILLY AND COMPANY 274 12.1.2.1 Business overview 274 12.1.2.2 Products offered 275 12.1.2.3 Recent developments 276 12.1.2.3.1 Deals 276 12.1.2.4 MnM view 276 12.1.2.4.1 Key strengths 276 12.1.2.4.2 Strategic choices 276 12.1.2.4.3 Weaknesses & competitive threats 276 12.1.3 TELEFLEX INCORPORATED 277 12.1.3.1 Business overview 277 12.1.3.2 Products offered 278 12.1.3.3 Recent developments 279 12.1.3.3.1 Product launches & approvals 279   12.1.3.4 MnM view 279 12.1.3.4.1 Key strengths 279 12.1.3.4.2 Strategic choices 279 12.1.3.4.3 Weaknesses & competitive threats 280 12.1.4 BOSTON SCIENTIFIC CORPORATION 281 12.1.4.1 Business overview 281 12.1.4.2 Recent developments 283 12.1.4.2.1 Deals 283 12.1.4.2.2 Expansions 283 12.1.4.3 MnM view 284 12.1.4.3.1 Key strengths 284 12.1.4.3.2 Strategic choices 284 12.1.4.3.3 Weaknesses & competitive threats 284 12.1.5 PROCEPT BIOROBOTICS CORPORATION 285 12.1.5.1 Business overview 285 12.1.5.2 Products offered 286 12.1.5.3 Recent developments 287 12.1.5.3.1 Product approvals 287 12.1.5.3.2 Expansions 287 12.1.5.4 MnM view 287 12.1.5.4.1 Key strengths 287 12.1.5.4.2 Strategic choices 287 12.1.5.4.3 Weaknesses & competitive threats 288 12.1.6 ASTELLAS PHARMA INC. 289 12.1.6.1 Business overview 289 12.1.6.2 Products offered 290 12.1.7 ALEMBIC PHARMACEUTICALS LIMITED 291 12.1.7.1 Business overview 291 12.1.7.2 Products offered 292 12.1.8 ASAHI KASEI CORPORATION 293 12.1.8.1 Business overview 293 12.1.8.2 Products offered 295 12.1.9 ORGANON & CO. 296 12.1.9.1 Business overview 296 12.1.9.2 Products offered 297 12.1.9.3 Recent developments 297 12.1.9.3.1 Deals 297 12.1.10 OLYMPUS CORPORATION 298 12.1.10.1 Business overview 298 12.1.10.2 Products offered 300 12.1.10.3 Recent developments 300 12.1.10.3.1 Deals 300 12.1.11 COLOPLAST GROUP 301 12.1.11.1 Business overview 301 12.1.11.2 Products offered 303 12.1.12 IPG PHOTONICS CORPORATION 304 12.1.12.1 Business overview 304 12.1.12.2 Products offered 305 12.1.13 VIATRIS INC. 306 12.1.13.1 Business overview 306 12.1.13.2 Products offered 307 12.1.14 ABBVIE INC. 308 12.1.14.1 Business overview 308 12.1.14.2 Products offered 309 12.1.14.3 Recent developments 310 12.1.14.3.1 Deals 310 12.1.15 PROSTALUND AB 311 12.1.15.1 Business overview 311 12.1.15.2 Products offered 312 12.2 OTHER PLAYERS 313 12.2.1 KARL STORZ SE & CO. KG 313 12.2.2 RICHARD WOLF GMBH 313 12.2.3 UNILAB, INC. 314 12.2.4 BIOLITEC HOLDING GMBH & CO KG 314 12.2.5 UROLOGIX, LLC. 315 12.2.6 ADVIN HEALTH CARE 315 12.2.7 MEDIFOCUS, INC. 316 12.2.8 JENASURGICAL (ASCLEPION LASER TECHNOLOGIES GMBH) 316 12.2.9 PNN MEDICAL A/S 317 12.2.10 SURGICAL LASERS INC. 317 12.2.11 QUANTA SYSTEM 318 12.2.12 ALLIUM LTD. 318 12.2.13 SRS MEDICAL 319 12.2.14 LABORIE MEDICAL TECHNOLOGIES 319 12.2.15 COOK MEDICAL 320 13 APPENDIX 321 13.1 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 325 13.2 CUSTOMIZATION OPTIONS 327 13.3 RELATED REPORTS 327 13.4 AUTHOR DETAILS 328

TABLE 1 BPH SURGICAL TREATMENT MARKET: RISK ASSESSMENT ANALYSIS 47 TABLE 2 ASSOCIATED SIDE EFFECTS OF BPH DRUGS 60 TABLE 3 PRODUCT RECALLS IN BPH TREATMENT MARKET 64 TABLE 4 BPH SURGICAL TREATMENT MARKET: ROLE OF COMPANIES IN ECOSYSTEM 68 TABLE 5 BPH SURGICAL TREATMENT MARKET: PORTER’S FIVE FORCES FACTOR ANALYSIS 69 TABLE 6 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER 71 TABLE 7 KEY BUYING CRITERIA (RANKING) FOR BPH SURGICAL TREATMENT MARKET, BY END USER 72 TABLE 8 US FDA: MEDICAL DEVICE CLASSIFICATION 74 TABLE 9 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 74 TABLE 10 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 75 TABLE 11 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA 76 TABLE 12 CHINA: CLASSIFICATION OF MEDICAL DEVICES 77 TABLE 13 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 80 TABLE 14 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 80 TABLE 15 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 81 TABLE 16 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 81 TABLE 17 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 82 TABLE 18 AVERAGE SELLING PRICE TREND FOR UROLIFT, BY REGION, 2021–2023 82 TABLE 19 AVERAGE SELLING PRICE TREND OF DUTASTERIDE (AVODART), BY REGION, 2021–2023 82 TABLE 20 AVERAGE SELLING PRICING TREND FOR BPH SURGICAL TREATMENT PROCEDURES, 2021–2023 83 TABLE 21 IMPORT DATA FOR ENDOSCOPES (VALUE) BY COUNTRY, 2019–2023 (USD THOUSAND) 90 TABLE 22 EXPORT DATA FOR ENDOSCOPES (VALUE) BY COUNTRY, 2019–2023 (USD THOUSAND) 90 TABLE 23 IMPORT DATA FOR TADALAFIL (VALUE) BY COUNTRY, 2019−2023 (USD THOUSAND) 91 TABLE 24 EXPORT DATA FOR TADALAFIL (VALUE) BY COUNTRY, 2019−2023 (USD THOUSAND) 91 TABLE 25 BPH SURGICAL TREATMENT MARKET: KEY CONFERENCES & EVENTS, 2025–2026 92 TABLE 26 BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE, 2022–2030 (USD MILLION) 96 TABLE 27 BPH DRUG TYPE MARKET, BY REGION, 2022–2030 (USD MILLION) 96 TABLE 28 NORTH AMERICA: BPH DRUG TYPE MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 97 TABLE 29 EUROPE: BPH DRUG TYPE MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 97 TABLE 30 ASIA PACIFIC: BPH DRUG TYPE MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 97 TABLE 31 LATIN AMERICA: BPH DRUG TYPE MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 98 TABLE 32 ALPHA-BLOCKERS MARKET, BY TYPE, 2022–2030 (USD MILLION) 98 TABLE 33 ALPHA-BLOCKERS MARKET, BY REGION, 2022–2030 (USD MILLION) 99 TABLE 34 NORTH AMERICA: ALPHA-BLOCKERS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 99 TABLE 35 EUROPE: ALPHA-BLOCKERS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 99 TABLE 36 ASIA PACIFIC: ALPHA-BLOCKERS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 100 TABLE 37 LATIN AMERICA: ALPHA-BLOCKERS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 100 TABLE 38 ALPHA-BLOCKERS MARKET FOR TAMSULOSIN, BY REGION, 2022–2030 (USD MILLION) 101 TABLE 39 NORTH AMERICA: ALPHA-BLOCKERS MARKET FOR TAMSULOSIN, BY COUNTRY, 2022–2030 (USD MILLION) 101 TABLE 40 EUROPE: ALPHA-BLOCKERS MARKET FOR TAMSULOSIN, BY COUNTRY, 2022–2030 (USD MILLION) 102 TABLE 41 ASIA PACIFIC: ALPHA-BLOCKERS MARKET FOR TAMSULOSIN, BY COUNTRY, 2022–2030 (USD MILLION) 102 TABLE 42 LATIN AMERICA: ALPHA-BLOCKERS MARKET FOR TAMSULOSIN, BY COUNTRY, 2022–2030 (USD MILLION) 103 TABLE 43 ALPHA-BLOCKERS MARKET FOR SILODOSIN, BY REGION, 2022–2030 (USD MILLION) 103 TABLE 44 NORTH AMERICA: ALPHA-BLOCKERS MARKET FOR SILODOSIN, BY COUNTRY, 2022–2030 (USD MILLION) 104 TABLE 45 EUROPE: ALPHA-BLOCKERS MARKET FOR SILODOSIN, BY COUNTRY, 2022–2030 (USD MILLION) 104 TABLE 46 ASIA PACIFIC: ALPHA-BLOCKERS MARKET FOR SILODOSIN, BY COUNTRY, 2022–2030 (USD MILLION) 105 TABLE 47 LATIN AMERICA: ALPHA-BLOCKERS MARKET FOR SILODOSIN, BY COUNTRY, 2022–2030 (USD MILLION) 105 TABLE 48 ALPHA-BLOCKERS MARKET FOR ALFUZOSIN, BY REGION, 2022–2030 (USD MILLION) 106 TABLE 49 NORTH AMERICA: ALPHA-BLOCKERS MARKET FOR ALFUZOSIN, BY COUNTRY, 2022–2030 (USD MILLION) 106 TABLE 50 EUROPE: ALPHA-BLOCKERS MARKET FOR ALFUZOSIN, BY COUNTRY, 2022–2030 (USD MILLION) 107 TABLE 51 ASIA PACIFIC: ALPHA-BLOCKERS MARKET FOR ALFUZOSIN, BY COUNTRY, 2022–2030 (USD MILLION) 107 TABLE 52 LATIN AMERICA: ALPHA-BLOCKERS MARKET FOR ALFUZOSIN, BY COUNTRY, 2022–2030 (USD MILLION) 108 TABLE 53 ALPHA-BLOCKERS MARKET FOR DOXAZOSIN, BY REGION, 2022–2030 (USD MILLION) 109 TABLE 54 NORTH AMERICA: ALPHA-BLOCKERS MARKET FOR DOXAZOSIN, BY COUNTRY, 2022–2030 (USD MILLION) 109 TABLE 55 EUROPE: ALPHA-BLOCKERS MARKET FOR DOXAZOSIN, BY COUNTRY, 2022–2030 (USD MILLION) 110 TABLE 56 ASIA PACIFIC: ALPHA-BLOCKERS MARKET FOR DOXAZOSIN, BY COUNTRY, 2022–2030 (USD MILLION) 110 TABLE 57 LATIN AMERICA: ALPHA-BLOCKERS MARKET FOR DOXAZOSIN, BY COUNTRY, 2022–2030 (USD MILLION) 111 TABLE 58 OTHER ALPHA-BLOCKERS MARKET, BY REGION, 2022–2030 (USD MILLION) 111 TABLE 59 NORTH AMERICA: OTHER ALPHA-BLOCKERS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 112 TABLE 60 EUROPE: OTHER ALPHA-BLOCKERS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 112 TABLE 61 ASIA PACIFIC: OTHER ALPHA-BLOCKERS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 113 TABLE 62 LATIN AMERICA: OTHER ALPHA-BLOCKERS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 113 TABLE 63 5-ALPHA REDUCTASE INHIBITORS MARKET, BY TYPE, 2022–2030 (USD MILLION) 114 TABLE 64 5-ALPHA REDUCTASE INHIBITORS MARKET, BY REGION, 2022–2030 (USD MILLION) 114 TABLE 65 NORTH AMERICA: 5-ALPHA REDUCTASE INHIBITORS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 114 TABLE 66 EUROPE: 5-ALPHA REDUCTASE INHIBITORS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 115 TABLE 67 ASIA PACIFIC: 5-ALPHA REDUCTASE INHIBITORS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 115 TABLE 68 LATIN AMERICA: 5-ALPHA REDUCTASE INHIBITORS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 116 TABLE 69 5-ALPHA REDUCTASE INHIBITORS FOR DUTASTERIDE MARKET, BY REGION, 2022–2030 (USD MILLION) 116 TABLE 70 NORTH AMERICA: 5-ALPHA REDUCTASE INHIBITORS MARKET FOR DUTASTERIDE, BY COUNTRY, 2022–2030 (USD MILLION) 117 TABLE 71 EUROPE: 5-ALPHA REDUCTASE INHIBITORS MARKET FOR DUTASTERIDE, BY COUNTRY, 2022–2030 (USD MILLION) 117 TABLE 72 ASIA PACIFIC: 5-ALPHA REDUCTASE INHIBITORS MARKET FOR DUTASTERIDE, BY COUNTRY, 2022–2030 (USD MILLION) 118 TABLE 73 LATIN AMERICA: 5-ALPHA REDUCTASE INHIBITORS MARKET FOR DUTASTERIDE, BY COUNTRY, 2022–2030 (USD MILLION) 118 TABLE 74 5-ALPHA REDUCTASE INHIBITORS MARKET FOR FINASTERIDE, BY REGION, 2022–2030 (USD MILLION) 119 TABLE 75 NORTH AMERICA: 5-ALPHA REDUCTASE INHIBITORS MARKET FOR FINASTERIDE, BY COUNTRY, 2022–2030 (USD MILLION) 119 TABLE 76 EUROPE: 5-ALPHA REDUCTASE INHIBITORS MARKET FOR FINASTERIDE, BY COUNTRY, 2022–2030 (USD MILLION) 120 TABLE 77 ASIA PACIFIC: 5-ALPHA REDUCTASE INHIBITORS MARKET FOR FINASTERIDE, BY COUNTRY, 2022–2030 (USD MILLION) 120 TABLE 78 LATIN AMERICA: 5-ALPHA REDUCTASE INHIBITORS MARKET FOR FINASTERIDE, BY COUNTRY, 2022–2030 (USD MILLION) 121 TABLE 79 OTHER DRUG TYPES MARKET, BY REGION, 2022–2030 (USD MILLION) 121 TABLE 80 NORTH AMERICA: OTHER DRUG TYPES MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 122 TABLE 81 EUROPE: OTHER DRUG TYPES MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 122 TABLE 82 ASIA PACIFIC: OTHER DRUG TYPES MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 122 TABLE 83 LATIN AMERICA: OTHER DRUG TYPES MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 123 TABLE 84 BPH SURGICAL TREATMENT MARKET, BY TYPE, 2022–2030 (USD MILLION) 125 TABLE 85 BPH TYPE MARKET, BY REGION, 2022–2030 (USD MILLION) 126 TABLE 86 NORTH AMERICA: BPH TYPE MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 126 TABLE 87 EUROPE: BPH TYPE MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 127 TABLE 88 ASIA PACIFIC: BPH TYPE MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 127 TABLE 89 LATIN AMERICA: BPH TYPE MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 128 TABLE 90 BPH SURGICAL TREATMENT MARKET FOR TURP, BY REGION, 2022–2030 (USD MILLION) 129 TABLE 91 NORTH AMERICA: BPH SURGICAL TREATMENT MARKET FOR TURP, BY COUNTRY, 2022–2030 (USD MILLION) 129 TABLE 92 EUROPE: BPH SURGICAL TREATMENT MARKET FOR TURP, BY COUNTRY, 2022–2030 (USD MILLION) 130 TABLE 93 ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET FOR TURP, BY COUNTRY, 2022–2030 (USD MILLION) 130 TABLE 94 LATIN AMERICA: BPH SURGICAL TREATMENT MARKET FOR TURP, BY COUNTRY, 2022–2030 (USD MILLION) 131 TABLE 95 BPH SURGICAL TREATMENT MARKET FOR LASER SURGERIES, BY REGION, 2022–2030 (USD MILLION) 131 TABLE 96 NORTH AMERICA: BPH SURGICAL TREATMENT MARKET FOR LASER SURGERIES, BY COUNTRY, 2022–2030 (USD MILLION) 132 TABLE 97 EUROPE: BPH SURGICAL TREATMENT MARKET FOR LASER SURGERIES, BY COUNTRY, 2022–2030 (USD MILLION) 132 TABLE 98 ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET FOR LASER SURGERIES, BY COUNTRY, 2022–2030 (USD MILLION) 133 TABLE 99 LATIN AMERICA: BPH SURGICAL TREATMENT MARKET FOR LASER SURGERIES, BY COUNTRY, 2022–2030 (USD MILLION) 133 TABLE 100 BPH SURGICAL TREATMENT MARKET FOR UROLIFT PROCEDURES, BY REGION, 2022–2030 (USD MILLION) 134 TABLE 101 NORTH AMERICA: BPH SURGICAL TREATMENT MARKET FOR UROLIFT PROCEDURES, BY COUNTRY, 2022–2030 (USD MILLION) 134 TABLE 102 EUROPE: BPH SURGICAL TREATMENT MARKET FOR UROLIFT PROCEDURES, BY COUNTRY, 2022–2030 (USD MILLION) 135 TABLE 103 ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET FOR UROLIFT PROCEDURES, BY COUNTRY, 2022–2030 (USD MILLION) 135 TABLE 104 LATIN AMERICA: BPH SURGICAL TREATMENT MARKET FOR UROLIFT PROCEDURES, BY COUNTRY, 2022–2030 (USD MILLION) 136 TABLE 105 BPH SURGICAL TREATMENT MARKET FOR REZŪM PROCEDURES, BY REGION, 2022–2030 (USD MILLION) 136 TABLE 106 NORTH AMERICA: BPH SURGICAL TREATMENT MARKET FOR REZŪM PROCEDURES, BY COUNTRY, 2022–2030 (USD MILLION) 137 TABLE 107 EUROPE: BPH SURGICAL TREATMENT MARKET FOR REZŪM PROCEDURES, BY COUNTRY, 2022–2030 (USD MILLION) 137 TABLE 108 ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET FOR REZŪM PROCEDURES, BY COUNTRY, 2022–2030 (USD MILLION) 138 TABLE 109 LATIN AMERICA: BPH SURGICAL TREATMENT MARKET FOR REZŪM PROCEDURES, BY COUNTRY, 2022–2030 (USD MILLION) 138 TABLE 110 BPH SURGICAL TREATMENT MARKET FOR ROBOT-ASSISTED WATERJET ABLATION, BY REGION, 2022–2030 (USD MILLION) 139 TABLE 111 NORTH AMERICA: BPH SURGICAL TREATMENT MARKET FOR ROBOT-ASSISTED WATERJET ABLATION, BY COUNTRY, 2022–2030 (USD MILLION) 139 TABLE 112 EUROPE: BPH SURGICAL TREATMENT MARKET FOR ROBOT-ASSISTED WATERJET ABLATION, BY COUNTRY, 2022–2030 (USD MILLION) 140 TABLE 113 ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET FOR ROBOT-ASSISTED WATERJET ABLATION, BY COUNTRY, 2022–2030 (USD MILLION) 140 TABLE 114 LATIN AMERICA: BPH SURGICAL TREATMENT MARKET FOR ROBOT-ASSISTED WATERJET ABLATION, BY COUNTRY, 2022–2030 (USD MILLION) 141 TABLE 115 BPH SURGICAL TREATMENT MARKET FOR PROSTATIC STENTING, BY REGION, 2022–2030 (USD MILLION) 142 TABLE 116 NORTH AMERICA: BPH SURGICAL TREATMENT MARKET FOR PROSTATIC STENTS, BY COUNTRY, 2022–2030 (USD MILLION) 142 TABLE 117 EUROPE: BPH SURGICAL TREATMENT MARKET FOR PROSTATIC STENTS, BY COUNTRY, 2022–2030 (USD MILLION) 143 TABLE 118 ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET FOR PROSTATIC STENTS, BY COUNTRY, 2022–2030 (USD MILLION) 143 TABLE 119 LATIN AMERICA: BPH SURGICAL TREATMENT MARKET FOR PROSTATIC STENTS, BY COUNTRY, 2022–2030 (USD MILLION) 144 TABLE 120 BPH SURGICAL TREATMENT MARKET FOR TUMT, BY REGION, 2022–2030 (USD MILLION) 144 TABLE 121 NORTH AMERICA: BPH SURGICAL TREATMENT MARKET FOR TUMT, BY COUNTRY, 2022–2030 (USD MILLION) 145 TABLE 122 EUROPE: BPH SURGICAL TREATMENT MARKET FOR TUMT, BY COUNTRY, 2022–2030 (USD MILLION) 145 TABLE 123 ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET FOR TUMT, BY COUNTRY, 2022–2030 (USD MILLION) 146 TABLE 124 LATIN AMERICA: BPH SURGICAL TREATMENT MARKET FOR TUMT, BY COUNTRY, 2022–2030 (USD MILLION) 146 TABLE 125 BPH SURGICAL TREATMENT MARKET FOR TUNA, BY REGION, 2022–2030 (USD MILLION) 147 TABLE 126 NORTH AMERICA: BPH SURGICAL TREATMENT MARKET FOR TUNA, BY COUNTRY, 2022–2030 (USD MILLION) 147 TABLE 127 EUROPE: BPH SURGICAL TREATMENT MARKET FOR TUNA, BY COUNTRY, 2022–2030 (USD MILLION) 148 TABLE 128 ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET FOR TUNA, BY COUNTRY, 2022–2030 (USD MILLION) 148 TABLE 129 LATIN AMERICA: BPH SURGICAL TREATMENT MARKET FOR TUNA, BY COUNTRY, 2022–2030 (USD MILLION) 149 TABLE 130 BPH SURGICAL TREATMENT MARKET FOR PAE, BY REGION, 2022–2030 (USD MILLION) 150 TABLE 131 NORTH AMERICA: BPH SURGICAL TREATMENT MARKET FOR PAE, BY COUNTRY, 2022–2030 (USD MILLION) 150 TABLE 132 EUROPE: BPH SURGICAL TREATMENT MARKET FOR PAE, BY COUNTRY, 2022–2030 (USD MILLION) 151 TABLE 133 ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET FOR PAE, BY COUNTRY, 2022–2030 (USD MILLION) 151 TABLE 134 LATIN AMERICA: BPH SURGICAL TREATMENT MARKET FOR PAE, BY COUNTRY, 2022–2030 (USD MILLION) 152 TABLE 135 BPH SURGICAL TREATMENT MARKET FOR OTHER PROCEDURES, BY REGION, 2022–2030 (USD MILLION) 152 TABLE 136 NORTH AMERICA: BPH DRUG TREATMENT MARKET FOR OTHER PROCEDURES, BY COUNTRY, 2022–2030 (USD MILLION) 153 TABLE 137 EUROPE: BPH DRUG TREATMENT MARKET FOR OTHER PROCEDURES, BY COUNTRY, 2022–2030 (USD MILLION) 153 TABLE 138 ASIA PACIFIC: BPH DRUG TREATMENT MARKET FOR OTHER PROCEDURES, BY COUNTRY, 2022–2030 (USD MILLION) 154 TABLE 139 LATIN AMERICA: BPH DRUG TREATMENT MARKET FOR OTHER PROCEDURES, BY COUNTRY, 2022–2030 (USD MILLION) 154 TABLE 140 BPH THERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION) 156 TABLE 141 BPH THERAPY MARKET, BY REGION, 2022–2030 (USD MILLION) 156 TABLE 142 NORTH AMERICA: BPH THERAPY MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 157 TABLE 143 EUROPE: BPH THERAPY MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 157 TABLE 144 ASIA PACIFIC: BPH THERAPY MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 157 TABLE 145 LATIN AMERICA: BPH THERAPY MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 158 TABLE 146 MONOTHERAPY MARKET, BY REGION, 2022–2030 (USD MILLION) 158 TABLE 147 NORTH AMERICA: MONOTHERAPY MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 159 TABLE 148 EUROPE: MONOTHERAPY MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 159 TABLE 149 ASIA PACIFIC: MONOTHERAPY MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 159 TABLE 150 LATIN AMERICA: MONOTHERAPY MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 160 TABLE 151 COMBINATION DRUG THERAPY MARKET, BY REGION, 2022–2030 (USD MILLION) 161 TABLE 152 NORTH AMERICA: COMBINATION DRUG THERAPY MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 161 TABLE 153 EUROPE: COMBINATION DRUG THERAPY MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 162 TABLE 154 ASIA PACIFIC: COMBINATION DRUG THERAPY MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 162 TABLE 155 LATIN AMERICA: COMBINATION DRUG THERAPY MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 163 TABLE 156 BPH SURGICAL TREATMENT MARKET, BY END USER, 2022–2030 (USD MILLION) 165 TABLE 157 BPH SURGICAL TREATMENT MARKET FOR HOSPITALS, BY REGION, 2022–2030 (USD MILLION) 166 TABLE 158 NORTH AMERICA: BPH SURGICAL TREATMENT MARKET FOR HOSPITALS, BY COUNTRY, 2022–2030 (USD MILLION) 166 TABLE 159 EUROPE: BPH SURGICAL TREATMENT MARKET FOR HOSPITALS, BY COUNTRY, 2022–2030 (USD MILLION) 167 TABLE 160 ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET FOR HOSPITALS, BY COUNTRY, 2022–2030 (USD MILLION) 167 TABLE 161 LATIN AMERICA: BPH SURGICAL TREATMENT MARKET FOR HOSPITALS, BY COUNTRY, 2022–2030 (USD MILLION) 168 TABLE 162 BPH SURGICAL TREATMENT MARKET FOR ASCS & CLINICS, BY REGION, 2022–2030 (USD MILLION) 169 TABLE 163 NORTH AMERICA: BPH SURGICAL TREATMENT MARKET FOR ASCS & CLINICS, BY COUNTRY, 2022–2030 (USD MILLION) 169 TABLE 164 EUROPE: BPH SURGICAL TREATMENT MARKET FOR ASCS & CLINICS, BY COUNTRY, 2022–2030 (USD MILLION) 170 TABLE 165 ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET FOR ASCS & CLINICS, BY COUNTRY, 2022–2030 (USD MILLION) 170 TABLE 166 LATIN AMERICA: BPH SURGICAL TREATMENT MARKET FOR ASCS & CLINICS, BY COUNTRY, 2022–2030 (USD MILLION) 171 TABLE 167 BPH SURGICAL TREATMENT MARKET FOR HOME CARE SETTINGS, BY REGION, 2022–2030 (USD MILLION) 172 TABLE 168 NORTH AMERICA: BPH SURGICAL TREATMENT MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2030 (USD MILLION) 172 TABLE 169 EUROPE: BPH SURGICAL TREATMENT MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2030 (USD MILLION) 173 TABLE 170 ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2030 (USD MILLION) 173 TABLE 171 LATIN AMERICA: BPH SURGICAL TREATMENT MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2030 (USD MILLION) 174 TABLE 172 BPH SURGICAL TREATMENT MARKET, BY REGION, 2022–2030 (USD MILLION) 176 TABLE 173 GLOBAL: ROBOT-ASSISTED WATERJET ABLATION SYSTEMS SOLD, 2022–2030 (MILLION UNITS) 176 TABLE 174 NORTH AMERICA: MACROINDICATORS 177 TABLE 175 NORTH AMERICA: BPH SURGICAL TREATMENT MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 178 TABLE 176 NORTH AMERICA: BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE, 2022–2030 (USD MILLION) 179 TABLE 177 NORTH AMERICA: BPH SURGICAL TREATMENT MARKET FOR ALPHA-BLOCKERS, BY TYPE, 2022–2030 (USD MILLION) 179 TABLE 178 NORTH AMERICA: BPH SURGICAL TREATMENT MARKET FOR 5-ALPHA REDUCTASE INHIBITORS, BY TYPE, 2022–2030 (USD MILLION) 179 TABLE 179 NORTH AMERICA: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2022–2030 (USD MILLION) 180 TABLE 180 NORTH AMERICA: BPH SURGICAL TREATMENT MARKET, BY THERAPY, 2022–2030 (USD MILLION) 180 TABLE 181 NORTH AMERICA: BPH SURGICAL TREATMENT MARKET, BY END USER, 2022–2030 (USD MILLION) 181 TABLE 182 US: BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE, 2022–2030 (USD MILLION) 182 TABLE 183 US: BPH SURGICAL TREATMENT MARKET FOR ALPHA-BLOCKERS, BY TYPE, 2022–2030 (USD MILLION) 182 TABLE 184 US: BPH SURGICAL TREATMENT MARKET FOR 5-ALPHA REDUCTASE INHIBITORS, BY TYPE, 2022–2030 (USD MILLION) 182 TABLE 185 US: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2022–2030 (USD MILLION) 183 TABLE 186 US: BPH SURGICAL TREATMENT MARKET, BY THERAPY, 2022–2030 (USD MILLION) 183 TABLE 187 US: BPH SURGICAL TREATMENT MARKET, BY END USER, 2022–2030 (USD MILLION) 184 TABLE 188 CANADA: BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE, 2022–2030 (USD MILLION) 185 TABLE 189 CANADA: BPH SURGICAL TREATMENT MARKET FOR ALPHA-BLOCKERS, BY TYPE, 2022–2030 (USD MILLION) 185 TABLE 190 CANADA: BPH SURGICAL TREATMENT MARKET FOR 5-ALPHA REDUCTASE INHIBITORS, BY TYPE, 2022–2030 (USD MILLION) 185 TABLE 191 CANADA: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2022–2030 (USD MILLION) 186 TABLE 192 CANADA: BPH SURGICAL TREATMENT MARKET, BY THERAPY, 2022–2030 (USD MILLION) 186 TABLE 193 CANADA: BPH SURGICAL TREATMENT MARKET, BY END USER, 2022–2030 (USD MILLION) 187 TABLE 194 EUROPE: MACROINDICATORS 188 TABLE 195 EUROPE: BPH SURGICAL TREATMENT MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 188 TABLE 196 EUROPE: BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE, 2022–2030 (USD MILLION) 189 TABLE 197 EUROPE: BPH SURGICAL TREATMENT MARKET FOR ALPHA-BLOCKERS, BY TYPE, 2022–2030 (USD MILLION) 189 TABLE 198 EUROPE: BPH SURGICAL TREATMENT MARKET FOR 5-ALPHA REDUCTASE INHIBITORS, BY TYPE, 2022–2030 (USD MILLION) 189 TABLE 199 EUROPE: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2022–2030 (USD MILLION) 190 TABLE 200 EUROPE: BPH SURGICAL TREATMENT MARKET, BY THERAPY, 2022–2030 (USD MILLION) 190 TABLE 201 EUROPE: BPH SURGICAL TREATMENT MARKET, BY END USER, 2022–2030 (USD MILLION) 191 TABLE 202 GERMANY: BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE, 2022–2030 (USD MILLION) 192 TABLE 203 GERMANY: BPH SURGICAL TREATMENT MARKET FOR ALPHA-BLOCKERS, BY TYPE, 2022–2030 (USD MILLION) 192 TABLE 204 GERMANY: BPH SURGICAL TREATMENT MARKET FOR 5-ALPHA REDUCTASE INHIBITORS, BY TYPE, 2022–2030 (USD MILLION) 192 TABLE 205 GERMANY: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2022–2030 (USD MILLION) 193 TABLE 206 GERMANY: BPH SURGICAL TREATMENT MARKET, BY THERAPY, 2022–2030 (USD MILLION) 193 TABLE 207 GERMANY: BPH SURGICAL TREATMENT MARKET, BY END USER, 2022–2030 (USD MILLION) 194 TABLE 208 UK: BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE, 2022–2030 (USD MILLION) 195 TABLE 209 UK: BPH SURGICAL TREATMENT MARKET FOR ALPHA-BLOCKERS, BY TYPE, 2022–2030 (USD MILLION) 195 TABLE 210 UK: BPH SURGICAL TREATMENT MARKET FOR 5-ALPHA REDUCTASE INHIBITORS, BY TYPE, 2022–2030 (USD MILLION) 195 TABLE 211 UK: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2022–2030 (USD MILLION) 196 TABLE 212 UK: BPH SURGICAL TREATMENT MARKET, BY THERAPY, 2022–2030 (USD MILLION) 196 TABLE 213 UK: BPH SURGICAL TREATMENT MARKET, BY END USER, 2022–2030 (USD MILLION) 197 TABLE 214 FRANCE: BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE, 2022–2030 (USD MILLION) 198 TABLE 215 FRANCE: BPH SURGICAL TREATMENT MARKET FOR ALPHA-BLOCKERS, BY TYPE, 2022–2030 (USD MILLION) 198 TABLE 216 FRANCE: BPH SURGICAL TREATMENT MARKET FOR 5-ALPHA REDUCTASE INHIBITORS, BY TYPE, 2022–2030 (USD MILLION) 198 TABLE 217 FRANCE: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2022–2030 (USD MILLION) 199 TABLE 218 FRANCE: BPH SURGICAL TREATMENT MARKET, BY THERAPY, 2022–2030 (USD MILLION) 199 TABLE 219 FRANCE: BPH SURGICAL TREATMENT MARKET, BY END USER, 2022–2030 (USD MILLION) 200 TABLE 220 ITALY: BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE, 2022–2030 (USD MILLION) 200 TABLE 221 ITALY: BPH SURGICAL TREATMENT MARKET FOR ALPHA-BLOCKERS, BY TYPE, 2022–2030 (USD MILLION) 201 TABLE 222 ITALY: BPH SURGICAL TREATMENT MARKET FOR 5-ALPHA REDUCTASE INHIBITORS, BY TYPE, 2022–2030 (USD MILLION) 201 TABLE 223 ITALY: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2022–2030 (USD MILLION) 202 TABLE 224 ITALY: BPH SURGICAL TREATMENT MARKET, BY THERAPY, 2022–2030 (USD MILLION) 202 TABLE 225 ITALY: BPH SURGICAL TREATMENT MARKET, BY END USER, 2022–2030 (USD MILLION) 203 TABLE 226 SPAIN: BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE, 2022–2030 (USD MILLION) 203 TABLE 227 SPAIN: BPH SURGICAL TREATMENT MARKET FOR ALPHA-BLOCKERS, BY TYPE, 2022–2030 (USD MILLION) 204 TABLE 228 SPAIN: BPH SURGICAL TREATMENT MARKET FOR 5-ALPHA REDUCTASE INHIBITORS, BY TYPE, 2022–2030 (USD MILLION) 204 TABLE 229 SPAIN: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2022–2030 (USD MILLION) 205 TABLE 230 SPAIN: BPH SURGICAL TREATMENT MARKET, BY THERAPY, 2022–2030 (USD MILLION) 205 TABLE 231 SPAIN: BPH SURGICAL TREATMENT MARKET, BY END USER, 2022–2030 (USD MILLION) 206 TABLE 232 REST OF EUROPE: BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE, 2022–2030 (USD MILLION) 206 TABLE 233 REST OF EUROPE: BPH SURGICAL TREATMENT MARKET FOR ALPHA-BLOCKERS, BY TYPE, 2022–2030 (USD MILLION) 207 TABLE 234 REST OF EUROPE: BPH SURGICAL TREATMENT MARKET FOR 5-ALPHA REDUCTASE INHIBITORS, BY TYPE, 2022–2030 (USD MILLION) 207 TABLE 235 REST OF EUROPE: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2022–2030 (USD MILLION) 208 TABLE 236 REST OF EUROPE: BPH SURGICAL TREATMENT MARKET, BY THERAPY, 2022–2030 (USD MILLION) 208 TABLE 237 REST OF EUROPE: BPH SURGICAL TREATMENT MARKET, BY END USER, 2022–2030 (USD MILLION) 209 TABLE 238 ASIA PACIFIC: MACROINDICATORS 209 TABLE 239 ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 211 TABLE 240 ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE, 2022–2030 (USD MILLION) 211 TABLE 241 ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET FOR ALPHA-BLOCKERS, BY TYPE, 2022–2030 (USD MILLION) 212 TABLE 242 ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET FOR 5-ALPHA REDUCTASE INHIBITORS, BY TYPE, 2022–2030 (USD MILLION) 212 TABLE 243 ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2022–2030 (USD MILLION) 213 TABLE 244 ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET, BY THERAPY, 2022–2030 (USD MILLION) 213 TABLE 245 ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET, BY END USER, 2022–2030 (USD MILLION) 214 TABLE 246 JAPAN: BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE, 2022–2030 (USD MILLION) 215 TABLE 247 JAPAN: BPH SURGICAL TREATMENT MARKET FOR ALPHA-BLOCKERS, BY TYPE, 2022–2030 (USD MILLION) 215 TABLE 248 JAPAN: BPH SURGICAL TREATMENT MARKET FOR 5-ALPHA REDUCTASE INHIBITORS, BY TYPE, 2022–2030 (USD MILLION) 215 TABLE 249 JAPAN: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2022–2030 (USD MILLION) 216 TABLE 250 JAPAN: BPH SURGICAL TREATMENT MARKET, BY THERAPY, 2022–2030 (USD MILLION) 216 TABLE 251 JAPAN: BPH SURGICAL TREATMENT MARKET, BY END USER, 2022–2030 (USD MILLION) 217 TABLE 252 CHINA: BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE, 2022–2030 (USD MILLION) 218 TABLE 253 CHINA: BPH SURGICAL TREATMENT MARKET FOR ALPHA-BLOCKERS, BY TYPE, 2022–2030 (USD MILLION) 218 TABLE 254 CHINA: BPH SURGICAL TREATMENT MARKET FOR 5-ALPHA REDUCTASE INHIBITORS, BY TYPE, 2022–2030 (USD MILLION) 219 TABLE 255 CHINA: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2022–2030 (USD MILLION) 219 TABLE 256 CHINA: BPH SURGICAL TREATMENT MARKET, BY THERAPY, 2022–2030 (USD MILLION) 220 TABLE 257 CHINA: BPH SURGICAL TREATMENT MARKET, BY END USER, 2022–2030 (USD MILLION) 220 TABLE 258 INDIA: BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE, 2022–2030 (USD MILLION) 221 TABLE 259 INDIA: BPH SURGICAL TREATMENT MARKET FOR ALPHA-BLOCKERS, BY TYPE, 2022–2030 (USD MILLION) 221 TABLE 260 INDIA: BPH SURGICAL TREATMENT MARKET FOR 5-ALPHA REDUCTASE INHIBITORS, BY TYPE, 2022–2030 (USD MILLION) 221 TABLE 261 INDIA: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2022–2030 (USD MILLION) 222 TABLE 262 INDIA: BPH SURGICAL TREATMENT MARKET, BY THERAPY, 2022–2030 (USD MILLION) 222 TABLE 263 INDIA: BPH SURGICAL TREATMENT MARKET, BY END USER, 2022–2030 (USD MILLION) 223 TABLE 264 AUSTRALIA: BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE, 2022–2030 (USD MILLION) 223 TABLE 265 AUSTRALIA: BPH SURGICAL TREATMENT MARKET FOR ALPHA-BLOCKERS, BY TYPE, 2022–2030 (USD MILLION) 224 TABLE 266 AUSTRALIA: BPH SURGICAL TREATMENT MARKET FOR 5-ALPHA REDUCTASE INHIBITORS, BY TYPE, 2022–2030 (USD MILLION) 224 TABLE 267 AUSTRALIA: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2022–2030 (USD MILLION) 225 TABLE 268 AUSTRALIA: BPH SURGICAL TREATMENT MARKET, BY THERAPY, 2022–2030 (USD MILLION) 225 TABLE 269 AUSTRALIA: BPH SURGICAL TREATMENT MARKET, BY END USER, 2022–2030 (USD MILLION) 226 TABLE 270 REST OF ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE, 2022–2030 (USD MILLION) 227 TABLE 271 REST OF ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET FOR ALPHA-BLOCKERS, BY TYPE, 2022–2030 (USD MILLION) 227 TABLE 272 REST OF ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET FOR 5-ALPHA REDUCTASE INHIBITORS, BY TYPE, 2022–2030 (USD MILLION) 227 TABLE 273 REST OF ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2022–2030 (USD MILLION) 228 TABLE 274 REST OF ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET, BY THERAPY, 2022–2030 (USD MILLION) 228 TABLE 275 REST OF ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET, BY END USER, 2022–2030 (USD MILLION) 229 TABLE 276 LATIN AMERICA: MACROINDICATORS 229 TABLE 277 LATIN AMERICA BPH SURGICAL TREATMENT MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 230 TABLE 278 LATIN AMERICA: BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE, 2022–2030 (USD MILLION) 230 TABLE 279 LATIN AMERICA: BPH SURGICAL TREATMENT MARKET FOR ALPHA-BLOCKERS, BY TYPE, 2022–2030 (USD MILLION) 230 TABLE 280 LATIN AMERICA: BPH SURGICAL TREATMENT MARKET FOR 5-ALPHA REDUCTASE INHIBITORS, BY TYPE, 2022–2030 (USD MILLION) 231 TABLE 281 LATIN AMERICA: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2022–2030 (USD MILLION) 231 TABLE 282 LATIN AMERICA: BPH SURGICAL TREATMENT MARKET, BY THERAPY, 2022–2030 (USD MILLION) 232 TABLE 283 LATIN AMERICA: BPH SURGICAL TREATMENT MARKET, BY END USER, 2022–2030 (USD MILLION) 232 TABLE 284 BRAZIL: BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE, 2022–2030 (USD MILLION) 233 TABLE 285 BRAZIL: BPH SURGICAL TREATMENT MARKET FOR ALPHA-BLOCKERS, BY TYPE, 2022–2030 (USD MILLION) 233 TABLE 286 BRAZIL: BPH SURGICAL TREATMENT MARKET FOR 5-ALPHA REDUCTASE INHIBITORS, BY TYPE, 2022–2030 (USD MILLION) 233 TABLE 287 BRAZIL: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2022–2030 (USD MILLION) 234 TABLE 288 BRAZIL: BPH SURGICAL TREATMENT MARKET, BY THERAPY, 2022–2030 (USD MILLION) 234 TABLE 289 BRAZIL: BPH SURGICAL TREATMENT MARKET, BY END USER, 2022–2030 (USD MILLION) 235 TABLE 290 MEXICO: BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE, 2022–2030 (USD MILLION) 236 TABLE 291 MEXICO: BPH SURGICAL TREATMENT MARKET FOR ALPHA-BLOCKERS, BY TYPE, 2022–2030 (USD MILLION) 236 TABLE 292 MEXICO: BPH SURGICAL TREATMENT MARKET FOR 5-ALPHA REDUCTASE INHIBITORS, BY TYPE, 2022–2030 (USD MILLION) 236 TABLE 293 MEXICO: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2022–2030 (USD MILLION) 237 TABLE 294 MEXICO: BPH SURGICAL TREATMENT MARKET, BY THERAPY, 2022–2030 (USD MILLION) 237 TABLE 295 MEXICO: BPH SURGICAL TREATMENT MARKET, BY END USER, 2022–2030 (USD MILLION) 238 TABLE 296 REST OF LATIN AMERICA: BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE, 2022–2030 (USD MILLION) 238 TABLE 297 REST OF LATIN AMERICA: BPH SURGICAL TREATMENT MARKET FOR ALPHA-BLOCKERS, BY TYPE, 2022–2030 (USD MILLION) 239 TABLE 298 REST OF LATIN AMERICA: BPH SURGICAL TREATMENT MARKET FOR 5-ALPHA REDUCTASE INHIBITORS, BY TYPE, 2022–2030 (USD MILLION) 239 TABLE 299 REST OF LATIN AMERICA: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2022–2030 (USD MILLION) 240 TABLE 300 REST OF LATIN AMERICA: BPH SURGICAL TREATMENT MARKET, BY THERAPY, 2022–2030 (USD MILLION) 240 TABLE 301 REST OF LATIN AMERICA: BPH SURGICAL TREATMENT MARKET, BY END USER, 2022–2030 (USD MILLION) 241 TABLE 302 MIDDLE EAST & AFRICA: MACROINDICATORS 242 TABLE 303 MIDDLE EAST & AFRICA: BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE, 2022–2030 (USD MILLION) 243 TABLE 304 MIDDLE EAST & AFRICA: BPH SURGICAL TREATMENT MARKET FOR ALPHA-BLOCKERS, BY TYPE, 2022–2030 (USD MILLION) 243 TABLE 305 MIDDLE EAST & AFRICA: BPH SURGICAL TREATMENT MARKET FOR 5-ALPHA REDUCTASE INHIBITORS, BY TYPE, 2022–2030 (USD MILLION) 243 TABLE 306 MIDDLE EAST & AFRICA: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2022–2030 (USD MILLION) 244 TABLE 307 MIDDLE EAST & AFRICA: BPH SURGICAL TREATMENT MARKET, BY THERAPY, 2022–2030 (USD MILLION) 244 TABLE 308 MIDDLE EAST & AFRICA: BPH SURGICAL TREATMENT MARKET, BY END USER, 2022–2030 (USD MILLION) 245 TABLE 309 GCC COUNTRIES: MACROINDICATORS 246 TABLE 310 GCC COUNTRIES: BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE, 2022–2030 (USD MILLION) 246 TABLE 311 GCC COUNTRIES: BPH SURGICAL TREATMENT MARKET FOR ALPHA-BLOCKERS, BY TYPE, 2022–2030 (USD MILLION) 247 TABLE 312 GCC COUNTRIES: BPH SURGICAL TREATMENT MARKET FOR 5-ALPHA REDUCTASE INHIBITORS, BY TYPE, 2022–2030 (USD MILLION) 247 TABLE 313 GCC COUNTRIES: BPH SURGICAL TREATMENT MARKET, BY TYPE, 2022–2030 (USD MILLION) 248 TABLE 314 GCC COUNTRIES: BPH SURGICAL TREATMENT MARKET, BY THERAPY, 2022–2030 (USD MILLION) 248 TABLE 315 GCC COUNTRIES: BPH SURGICAL TREATMENT MARKET, BY END USER, 2022–2030 (USD MILLION) 249 TABLE 316 OVERVIEW OF STRATEGIES ADOPTED BY KEY MARKET PLAYERS 250 TABLE 317 BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE: DEGREE OF COMPETITION 253 TABLE 318 BPH SURGICAL TREATMENT MARKET, BY TYPE: DEGREE OF COMPETITION 255 TABLE 319 BPH SURGICAL TREATMENT MARKET: COMPANY FOOTPRINT 260 TABLE 320 BPH SURGICAL TREATMENT MARKET: REGION FOOTPRINT 261 TABLE 321 BPH SURGICAL TREATMENT MARKET: DRUG TYPE FOOTPRINT 261 TABLE 322 BPH SURGICAL TREATMENT MARKET: TYPE FOOTPRINT 262 TABLE 323 BPH SURGICAL TREATMENT MARKET: END-USER FOOTPRINT 262 TABLE 324 BPH SURGICAL TREATMENT MARKET: DETAILED LIST OF KEY SME PLAYERS 265 TABLE 325 BPH SURGICAL TREATMENT MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS 265 TABLE 326 BPH SURGICAL TREATMENT MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–JANUARY 2025 267 TABLE 327 BPH SURGICAL TREATMENT MARKET: DEALS, JANUARY 2021–JANUARY 2025 268 TABLE 328 BPH SURGICAL TREATMENT MARKET: EXPANSIONS, JANUARY 2021–JANUARY 2025 269 TABLE 329 GLAXOSMITHKLINE PLC: COMPANY OVERVIEW 270 TABLE 330 GLAXOSMITHKLINE PLC: PRODUCTS OFFERED 272 TABLE 331 GLAXOSMITHKLINE PLC: DEALS, JANUARY 2021–JANUARY 2025 272 TABLE 332 ELI LILLY AND COMPANY: COMPANY OVERVIEW 274 TABLE 333 ELI LILLY AND COMPANY: PRODUCTS OFFERED 275 TABLE 334 ELI LILLY AND COMPANY: DEALS, JANUARY 2021–JANUARY 2025 276 TABLE 335 TELEFLEX INCORPORATED: COMPANY OVERVIEW 277 TABLE 336 TELEFLEX INCORPORATED: PRODUCTS OFFERED 278 TABLE 337 TELEFLEX INCORPORATED: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–JANUARY 2025 279 TABLE 338 BOSTON SCIENTIFIC CORPORATION: COMPANY OVERVIEW 281 TABLE 339 BOSTON SCIENTIFIC CORPORATION: PRODUCTS OFFERED 282 TABLE 340 BOSTON SCIENTIFIC CORPORATION: DEALS, JANUARY 2021–JANUARY 2025 283 TABLE 341 BOSTON SCIENTIFIC CORPORATION: EXPANSIONS, JANUARY 2021–JANUARY 2025 283 TABLE 342 PROCEPT BIOROBOTICS CORPORATION: COMPANY OVERVIEW 285 TABLE 343 PROCEPT BIOROBOTICS CORPORATION: PRODUCTS OFFERED 286 TABLE 344 PROCEPT BIOROBOTICS CORPORATION: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–JANUARY 2025 287 TABLE 345 PROCEPT BIOROBOTICS CORPORATION: EXPANSIONS, JANUARY 2021–JANUARY 2025 287 TABLE 346 ASTELLAS PHARMA INC.: COMPANY OVERVIEW 289 TABLE 347 ASTELLAS PHARMA INC.: PRODUCTS OFFERED 290 TABLE 348 ALEMBIC PHARMACEUTICALS LIMITED: COMPANY OVERVIEW 291 TABLE 349 ALEMBIC PHARMACEUTICALS LIMITED: PRODUCTS OFFERED 292 TABLE 350 ASAHI KASEI CORPORATION: COMPANY OVERVIEW 293 TABLE 351 ASAHI KASEI CORPORATION: PRODUCTS OFFERED 295 TABLE 352 ORGANON & CO.: COMPANY OVERVIEW 296 TABLE 353 ORGANON & CO.: PRODUCTS OFFERED 297 TABLE 354 ORGANON & CO.: DEALS, JANUARY 2021–JANUARY 2025 297 TABLE 355 OLYMPUS CORPORATION: COMPANY OVERVIEW 298 TABLE 356 OLYMPUS CORPORATION: PRODUCTS OFFERED 300 TABLE 357 OLYMPUS CORPORATION: DEALS, JANUARY 2021–JANUARY 2021 300 TABLE 358 COLOPLAST GROUP: COMPANY OVERVIEW 301 TABLE 359 COLOPLAST GROUP: PRODUCTS OFFERED 303 TABLE 360 IPG PHOTONICS CORPORATION: COMPANY OVERVIEW 304 TABLE 361 IPG PHOTONICS CORPORATION: PRODUCTS OFFERED 305 TABLE 362 VIATRIS INC.: COMPANY OVERVIEW 306 TABLE 363 VIATRIS INC.: PRODUCTS OFFERED 307 TABLE 364 ABBVIE INC.: COMPANY OVERVIEW 308 TABLE 365 ABBVIE INC.: PRODUCTS OFFERED 309 TABLE 366 ABBVIE INC.: DEALS, JANUARY 2021–JANUARY 2025 310 TABLE 367 PROSTALUND AB: COMPANY OVERVIEW 311 TABLE 368 PROSTALUND AB: PRODUCTS OFFERED 312 _ FIGURE 1 MARKETS & REGIONS COVERED 30 FIGURE 2 RESEARCH DESIGN 34 FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 38 FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 39 FIGURE 5 BPH SURGICAL TREATMENT MARKET: REVENUE ESTIMATION APPROACH, BY TYPE 40 FIGURE 6 BPH SURGICAL TREATMENT MARKET: REVENUE ESTIMATION APPROACH, BY DRUG TYPE 41 FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 43 FIGURE 8 BPH SURGICAL TREATMENT MARKET: TOP-DOWN APPROACH 44 FIGURE 9 DATA TRIANGULATION METHODOLOGY 45 FIGURE 10 BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE, 2024 VS. 2030 (USD MILLION) 48 FIGURE 11 BPH SURGICAL TREATMENT MARKET, BY TYPE, 2024 VS. 2030 (USD MILLION) 49 FIGURE 12 BPH SURGICAL TREATMENT MARKET, BY THERAPY, 2024 VS. 2030 (USD MILLION) 50 FIGURE 13 BPH SURGICAL TREATMENT, BY END USER, 2024 VS. 2030 (USD MILLION) 51 FIGURE 14 GEOGRAPHIC SNAPSHOT OF BPH SURGICAL TREATMENT MARKET 52 FIGURE 15 EXPANDING GERIATRIC POPULATION AND INCREASING PREVALENCE OF BENIGN PROSTATIC HYPERPLASIA TO PROPEL MARKET 53 FIGURE 16 ALPHA-BLOCKERS SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN US IN 2023 54 FIGURE 17 CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 55 FIGURE 18 ASIA PACIFIC REGION TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD 56 FIGURE 19 BPH TREATMENT MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 57 FIGURE 20 BHP SURGICAL TREATMENT MARKET: MAJOR VALUE ADDED DURING MANUFACTURING & ASSEMBLY PHASES 65 FIGURE 21 BPH SURGICAL TREATMENT MARKET: SUPPLY CHAIN ANALYSIS 66 FIGURE 22 BPH SURGICAL TREATMENT MARKET: ECOSYSTEM ANALYSIS 67 FIGURE 23 KEY PLAYERS IN BPH SURGICAL TREATMENT MARKET ECOSYSTEM 68 FIGURE 24 BPH SURGICAL TREATMENT MARKET: PORTER’S FIVE FORCES ANALYSIS 69 FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR BPH SURGICAL TREATMENT MARKET 71 FIGURE 26 KEY BUYING CRITERIA FOR BPH SURGICAL TREATMENT, BY END USER 71 FIGURE 27 BPH SURGICAL TREATMENT MARKET: PESTLE ANALYSIS 85 FIGURE 28 PATENT ANALYSIS FOR PROSTATIC STENTS: JANUARY 2015–DECEMBER 2024 86 FIGURE 29 PATENT ANALYSIS FOR TRANSURETHRAL CATHETERS: JANUARY 2015–DECEMBER 2024 87 FIGURE 30 PATENT ANALYSIS FOR AVODART: JANUARY 2015–DECEMBER 2024 88 FIGURE 31 PATENT ANALYSIS FOR ALFUZOSIN: JANUARY 2015–DECEMBER 2024 89 FIGURE 32 TRENDS AND DISRUPTIONS IMPACTING CUSTOMER BUSINESSES IN BPH SURGICAL TREATMENT MARKET 93 FIGURE 33 BPH SURGICAL TREATMENT MARKET: NUMBER OF DEALS & VENTURES 94 FIGURE 34 NORTH AMERICA: BPH SURGICAL TREATMENT MARKET SNAPSHOT 178 FIGURE 35 ASIA PACIFIC: BPH SURGICAL TREATMENT MARKET SNAPSHOT 210 FIGURE 36 REVENUE ANALYSIS OF KEY PLAYERS IN BPH SURGICAL TREATMENT, 2021−2023 252 FIGURE 37 MARKET SHARE ANALYSIS OF KEY PLAYERS IN BPH SURGICAL TREATMENT MARKET, BY DRUG TYPE (2023) 253 FIGURE 38 MARKET SHARE ANALYSIS OF KEY PLAYERS IN BPH SURGICAL TREATMENT MARKET, BY TYPE (2023) 254 FIGURE 39 BPH SURGICAL TREATMENT MARKET: COMPANY EVALUATION MATRIX FOR DRUG TYPE (KEY PLAYERS), 2023 257 FIGURE 40 BPH SURGICAL TREATMENT MARKET: COMPANY EVALUATION MATRIX FOR TYPE, (KEY PLAYERS), 2023 259 FIGURE 41 BPH SURGICAL TREATMENT MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023 264 FIGURE 42 EV/EBITDA OF KEY VENDORS, 2023−2024 266 FIGURE 43 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 266 FIGURE 44 BPH SURGICAL TREATMENT MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 267 FIGURE 45 GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT (2023) 271 FIGURE 46 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2023) 275 FIGURE 47 TELEFLEX INCORPORATED: COMPANY SNAPSHOT (2023) 278 FIGURE 48 BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT (2023) 282 FIGURE 49 PROCEPT BIOROBOTICS CORPORATION: COMPANY SNAPSHOT (2023) 286 FIGURE 50 ASTELLAS PHARMA INC.: COMPANY SNAPSHOT (2023) 289 FIGURE 51 ALEMBIC PHARMACEUTICALS LIMITED: COMPANY SNAPSHOT (2023) 291 FIGURE 52 ASAHI KASEI CORPORATION: COMPANY SNAPSHOT (2023) 294 FIGURE 53 ORGANON & CO.: COMPANY SNAPSHOT (2023) 296 FIGURE 54 OLYMPUS CORPORATION: COMPANY SNAPSHOT (2023) 299 FIGURE 55 COLOPLAST GROUP: COMPANY SNAPSHOT (2024) 302 FIGURE 56 IPG PHOTONICS CORPORATION: COMPANY SNAPSHOT (2023) 305 FIGURE 57 VIATRIS INC.: COMPANY SNAPSHOT (2023) 306 FIGURE 58 ABBVIE INC.: COMPANY SNAPSHOT (2023) 309 FIGURE 59 PROSTALUND AB: COMPANY SNAPSHOT (2023) 311